Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

Dr Alexandros Rampotas speaks to ecancer about the development and evaluation of a CAR-T cell therapy targeting mutCALR+ neoplasms.
Mutant calreticulin (CALR) is an attractive immunotherapy target. This study was conducted to pre-clinically validate a second-generation, 4-1BB chimeric antigen receptor T-cell (CAR-T) therapy designed to target mutant CALR (mutCALR) driven myeloproliferative neoplasms.
As a result of this study, a first-in-class CAR-T cell therapeutic to target mutCALR-driven myeloproliferative blood cancers has been developed.
Dr Rampotas concluded by discussing the significance of this study and its next steps.